Back to Search

Daunorubicin,Cytarabine – Uses, Dosage, and Brands in UAE

Brand Name: Vyxeos
Strength: 44 mg,100 mg | Form: Liposomal 44 mg/100 mg powder for concentrate for solution for infusion
Price in UAE: AED 25547.10
Available in UAE pharmacies

About Daunorubicin,Cytarabine

Class: | Antineoplastic agent, Combination chemotherapy (liposomal formulation) Use: | Treatment of adults with newly diagnosed acute myeloid leukemia (AML) and secondary AML Adult dose: | Recommended dose is 44 mg/m² daunorubicin and 100 mg/m² cytarabine administered as a continuous intravenous infusion over 90 minutes on days 1, 3, and 5 of a 28-day cycle Pediatric dose: | Safety and efficacy in pediatric patients have not been established; use is not recommended Side effects: | Common

Drug Class

Antineoplastic agent, Combination chemotherapy (liposomal formulation)

Uses & Indications

Treatment of adults with newly diagnosed acute myeloid leukemia (AML) and secondary AML

Storage Requirements

Store at 2°C to 8°C (36°F to 46°F); do not freeze; protect from light; once reconstituted, use immediately or store at 2°C to 8°C for up to 24 hours

Manufacturer & Packaging

Manufacturer: JAZZ Pharmaceutical Ireland Limited , Ireland

Package Size

1's

Price & Supplier

Price in UAE: AED 25547.10

Dosage Information

Adult Dose

Recommended dose is 44 mg/m² daunorubicin and 100 mg/m² cytarabine administered as a continuous intravenous infusion over 90 minutes on days 1, 3, and 5 of a 28-day cycle

Pediatric Dose

Safety and efficacy in pediatric patients have not been established; use is not recommended

Side Effects

Common side effects include nausea, vomiting, fever, fatigue, low blood cell counts (neutropenia, thrombocytopenia, anemia), and infusion-related reactions

Contraindications & Precautions

Hypersensitivity to daunorubicin, cytarabine, or any component of the formulation; patients with severe hepatic impairment; active infections; pregnancy and breastfeeding

Important Warnings

Risk of serious adverse reactions including severe myelosuppression, infections, cardiotoxicity, and infusion-related reactions; monitor blood counts and cardiac function; avoid use in patients with a history of congestive heart failure or significant arrhythmias

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication. The information presented here is specific to medicines available in UAE pharmacies and is regularly updated to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.

View All Antineoplastic agent, Combination chemotherapy (liposomal formulation) Medicines Browse All Categories